(Circulation. 1995;91:813-820.)
© 1995 American Heart Association, Inc.
Articles |
From the Experimental Cardiology Laboratory, Division of Cardiology, Department of Medicine, University of Virginia, Charlottesville.
| Abstract |
|---|
|
|
|---|
Methods and Results Twenty-two dogs were instrumented with flow transducers on the left anterior descending (LAD) and circumflex (LCx) arteries. In 6 nonstenotic dogs, adenosine was infused directly into the LAD, whereas 16 dogs with either critical (n=7) or mild (n=9) LAD stenoses received an intravenous infusion. At peak flow, 201Tl (0.5 mCi), sestamibi (5 to 8 mCi), and radiolabeled microspheres were injected simultaneously. Five minutes later, dogs were killed, and ex vivo imaging of heart slices and gamma-well counting of multiple myocardial samples was performed. Neither 201Tl nor sestamibi uptake increased in direct proportion to flow. In the 6 nonstenotic dogs, a fivefold increase in LAD flow increased 201Tl and sestamibi uptake by only 202±6% and 138±4%, respectively (P<.0001). In the dogs with critical stenosis, the ratios of stenotic to normal activity by well counting for 201Tl (0.37±0.05) and sestamibi (0.53±0.06) underestimated the microsphere-determined flow disparity (0.17±0.03) (P<.005), but the degree of underestimation was greater for sestamibi (P=.001). Similarly, in the dogs with mild stenosis, the stenotic-to-normal ratio for 201Tl (0.62±0.04) approximated the flow ratio (0.43±0.04) better than sestamibi (0.79±0.03) (P<.0001). Sestamibi defects, however, were visually identifiable on the images of the myocardial slices. By image quantification, sestamibi defect magnitude (LAD-to-LCx count ratio) in the critical stenosis group (0.62±0.05) was significantly less than in the mild stenosis group (0.80±0.02) (P<.01).
Conclusions Thus, with adenosine-induced hyperemic flow, both 201Tl and sestamibi significantly underestimated the magnitude of the flow disparity between stenotic and normal perfusion beds. The degree of underestimation was greater for sestamibi. The clinical implication of these experimental findings for vasodilator perfusion imaging remains to be determined, since factors such as greater redistribution and scatter with 201Tl could offset its advantages.
Key Words: vasodilation ischemia isonitrile
| Introduction |
|---|
|
|
|---|
The goals of the present study were (1) to compare the myocardial uptake of 201Tl with sestamibi during adenosine-induced hyperemia by use of quantification of flow and tracer activities and (2) to compare defect magnitudes on sestamibi images in dogs with mild versus severe stenoses. The hypothesis tested in this study was that myocardial 201Tl uptake patterns should be less affected by the plateau in tracer extraction at high flows than sestamibi.
| Methods |
|---|
|
|
|---|
A thoracotomy was performed at the level of the fifth intercostal space, and the heart was suspended in a pericardial cradle. A flare-tipped polyethylene catheter was inserted into the left atrial appendage for continuous left atrial pressure measurements and as a site for the injection of radiolabeled microspheres. The left anterior descending coronary artery (LAD) was then dissected free of the epicardium, and an ultrasonic flow probe (T201, Transonic Systems, Inc) and snare ligature were placed around the vessel. A similar flow probe was placed around the left circumflex artery (LCx). In the 6 dogs receiving intracoronary infusions of adenosine, the 27-gauge needle of a lymphangiography catheter (catalog No. 6656, Becton, Dickinson & Co) was carefully inserted through the LAD wall proximal to the flow probe, and the catheter was anchored in place with several sutures to the myocardial wall. The hemodynamic parameters of heart rate, systemic arterial and left atrial pressures, and LAD and LCx flows were continuously recorded on an eight-channel strip-chart recorder (model 7758D, Hewlett-Packard) throughout each protocol. All experiments were performed with the approval of the University of Virginia Animal Research Committee in compliance with the position of the American Heart Association on use of research animals.
Experimental Protocols
Protocol 1: Intracoronary
Adenosine (n=6)
An intracoronary infusion of adenosine was
begun into the
lymphangiography catheter at a rate of 0.25 mL/min, and the rate was
adjusted to maintain mean ultrasonic LAD flow at two to three times
baseline without raising LCx flow above 1.5 times its baseline value.
Three dogs were then given a simultaneous injection of 8 mCi of
99mTc-sestamibi and 0.5 mCi of 201Tl. Three
additional dogs were injected solely with 99mTc-sestamibi
to determine whether flow-uptake values were comparable to those seen
with the dual-isotope protocol. The tracer injections were followed
within 1 to 2 minutes by a left atrial injection of radiolabeled
microspheres. All dogs were killed 5 minutes after tracer
administrations.
Protocols 2 and 3: Intravenous Adenosine,
Either Critical or Mild
LAD Stenoses
Protocols 2 and 3 are shown schematically in Fig
1
. During the baseline period, before the coronary
stenosis was set, microspheres were administered to measure baseline
flow. Microspheres were labeled with either 103Ru,
95Nb, or 46Sc. The selection order of
microspheres was randomized to minimize bias. To measure the normal
reactive hyperemic response, the LAD was then briefly occluded by
tightening the snare occluder for 10 seconds and releasing it to
produce a reactive hyperemia flow tracing on the strip-chart recorder.
In protocol 2, the snare was then adjusted to produce a critical
stenosis. A critical stenosis was defined as the point at which
baseline flow was unchanged but the reactive hyperemic response was
completely abolished. A second injection of microspheres was
administered after the stenosis was set. Next, an intravenous infusion
of adenosine was begun at a rate of 300
µg · kg-1 · min-1 and
continued
until LCx flow was maximal. This dose of adenosine was chosen
empirically to produce high coronary flow without decreasing systemic
arterial pressure below 85 mm Hg. When maximal LCx flow was achieved,
0.5 mCi of 201Tl, 5 mCi of sestamibi, and microspheres were
injected simultaneously. Five minutes later, before the thallium could
undergo appreciable redistribution, the dogs were killed.
|
In protocol 3, the snare was adjusted to produce a mild LAD stenosis. A mild stenosis was defined as no change in baseline flow but a 50% reduction in the reactive hyperemic test response. The remainder of protocol 3 was identical to that of protocol 2.
Ex Vivo
Slice Imaging (Protocols 2 and 3 Only)
After the dogs were killed, the
hearts were removed and sliced
into four rings
1 cm thick from apex to base. The slices were
trimmed of excess fat and adventitia and placed on a thin piece of
cardboard covered with cellophane wrap. The slices were imaged directly
on the collimator of a conventional planar gamma camera for maximal
count time (1638 seconds). The slices were imaged with a 20% window
centered on the 99mTc photopeak, and image quantification
was performed on a standard nuclear medicine computer system (Sopha
Medical Systems). Regions of interest were drawn on the defect area
visible in the anteroapical region of the left ventricular wall and on
the normal posterior wall of the sestamibi images. Quantification was
performed only on the two center slices, since the basal slice was
above the stenosis and hence was always normal, whereas the apical
slice lacked a quantifiable normal region. The defect magnitude was
calculated as the ratio of the average counts in the LAD region of
interest divided by the average counts in the normal LCx region of
interest. Because of spilldown of 99mTc into the
201Tl window, quantification of 201Tl defect
magnitude could not be performed accurately.
Quantification
of Myocardial 201Tl, Sestamibi, and
Microsphere Flow
To measure 201Tl and sestamibi activities
and
microsphere-determined flow in the myocardial tissue samples, each of
the four myocardial slices was divided into eight transmural sections,
which were then further subdivided into epicardial, midwall, and
endocardial segments, resulting in a total of 96 myocardial segments
for each dog. The myocardial tissue samples were counted in a
gamma-well scintillation counter (MINAXI 5550, Packard Instruments) for
both 201Tl and 99mTc activities within 24 hours
of collection. The samples were recounted for microsphere flows 2 weeks
later when the 201Tl and 99mTc had decayed. The
window settings on the gamma counter were 201Tl, 50 to 100
keV; 99mTc, 130 to 170 keV; 103Ru, 450 to 550
keV; 95Nb, 640 to 840 keV; and 46Sc, 842 to
1300 keV. The tissue counts were corrected for background, decay, and
isotope spillover, and regional myocardial blood flow was calculated
with specialized computer software (PCGERDA, Packard
Instruments). Transmural activity and flow values were calculated as
the average of the corresponding epicardial, midwall, and endocardial
samples. The microsphere technique used in our laboratory has been
described.21
Data Analysis and Statistics
All statistical computations
were made with SYSTAT
software (SYSTAT Inc). The results were expressed as the mean±SEM.
Differences between means within a group were assessed by a paired
t test, with values of P<.05 considered
significant. Comparisons between the two groups were made with one-way
ANOVA and Tukey's post hoc testing.
| Results |
|---|
|
|
|---|
|
Regional Flow Versus 201Tl and
Sestamibi Activities
In this protocol, adenosine was injected directly
into the normal
LAD, after which 201Tl and sestamibi were administered
intravenously. Myocardial segments from all dogs were grouped into flow
ranges according to regional flow values at the time of tracer
injection (Fig 2
). Neither 201Tl nor
sestamibi activity increased in direct proportion to blood flow.
Sestamibi activity was significantly less than 201Tl
activity in all flow ranges, and the difference between the tracers
became progressively larger as flow increased. A fivefold to sixfold
increase in regional myocardial blood flow increased 201Tl
uptake by 202±6% but increased sestamibi uptake by only 138±4%
(P<.0001) (Fig 2
).
|
Protocol 2: Assessment of 201Tl and Sestamibi Uptake
During Intravenous Adenosine Infusion in the Setting of a Critical LAD
Stenosis
Hemodynamic Data
The hemodynamic variables
measured throughout the protocol are
summarized in Table 1
. In all dogs in this protocol, there was
a
biphasic mean arterial pressure response to the intravenous adenosine
infusion. At the onset of the infusion, mean arterial pressure fell
rapidly at first, but after a nonsignificant reflex rise in heart rate,
mean pressure increased and then remained near 85 mm Hg. In this
group, adenosine produced a slight increase in left atrial pressure.
The mean LAD flow was 17±1 mL/min at baseline and was not
significantly altered after the critical stenosis was set (15±1
mL/min). As seen in Fig 3
, there was also no change in
the stenotic LAD flow after adenosine infusion (13±2 mL/min). Mean LCx
flow was 28±6 mL/min at baseline and 29±7 mL/min after the LAD
stenosis was set (P=NS). With adenosine, there was a
fourfold increase in LCx flow, to 106±18 mL/min
(P=.003).
|
Regional Flow Changes With
Setting of the Critical LAD Stenosis and
After Adenosine Infusion
In this protocol, adenosine was administered
intravenously to dogs
with a critical stenosis. Table 2
summarizes the
regional myocardial blood flow for this group of dogs during baseline,
after the stenosis was set, and during adenosine-induced
hyperemia, when 201Tl and sestamibi were administered. As
shown, there was no change in resting epicardial, midwall, or
endocardial flow after the LAD stenosis was set. In this group, flow in
the epicardial region of the LAD zone did not change during
adenosine-induced hyperemia (1.2±0.1 versus 1.1±0.1
mL · min-1 · g-1). However, in
the
midwall and endocardial regions of the LAD zone, flow fell
significantly, from 1.1±0.2 and 1.0±0.2
mL · min-1 · g-1 to
0.6±0.1 and
0.3±0.1
mL · min-1 · g-1,
respectively (P<.04), with a resultant decrease in the
endocardial-to-epicardial flow ratio from 0.8±0.1 to 0.3±0.1
(P=.02), presumably because of coronary steal. Flow
increased significantly in all layers of the normal LCx zone after
adenosine administration. There was a significant decrease in the
endocardial-to-epicardial flow ratio in the LCx zone during adenosine
(from 1.1±0.0 to 0.6±0.1
mL · min-1 · g-1)
(P<.05)
resulting from a greater increase in epicardial flow relative to
endocardial flow in the nonstenotic LCx zone.
|
Myocardial
201Tl and Sestamibi Activities After Tracer
Administration During Adenosine Infusion
In Fig 4
,
201Tl and sestamibi
activities in 32 transmural segments are plotted against the
corresponding microsphere flow at the time of injection in a
representative dog in this group with a critical LAD stenosis.
As shown, the myocardial uptake of both 201Tl and sestamibi
plateaued with increasing flow. Note that myocardial sestamibi activity
was significantly less than that of 201Tl at flows >150%
of normal.
|
Fig 5
(left) displays the mean ratios of
stenotic to
normal zones for microsphere flow, 201Tl, and sestamibi
determined from gamma-well counting of myocardial segments in the group
of dogs that received adenosine in the setting of a critical LAD
stenosis. These ratios are reflective of the relative decrease in
microsphere and tracer concentrations in the stenotic coronary bed of
the LAD. In the stenosis group, the ratios for both 201Tl
(0.37±0.05) and sestamibi (0.53±0.06) significantly
underestimated
the actual ratio of stenotic to normal flow (0.17±0.03)
(P<.005). The degree of this flow underestimation was
greater for sestamibi versus 201Tl (P=.001).
|
Protocol 3: Assessment of 201Tl and Sestamibi Uptake
During Intravenous Adenosine Infusion in the Setting of a Mild LAD
Stenosis
Hemodynamic Data
As observed in the dogs with a
critical stenosis, a decrease in
arterial pressure and increase in heart rate were seen in these dogs
with a mild LAD stenosis. The mean LAD and LCx flows as measured by the
ultrasonic flowmeter in the mildly stenotic dogs in protocol 3 are
summarized in Fig 3
. Mean LAD flow was unchanged after the mild
stenosis was set (25±2 versus 24±2 mL/min). With adenosine, a
significant increase in LAD flow to 47±5 mL/min (P<.001)
occurred. Flow in the LCx bed was 32±3 mL/min at baseline
(P=NS versus LAD baseline flow) and 32±3 mL/min after
the
LAD stenosis was set (P=NS). During the adenosine infusion,
there was a nearly fourfold increase in LCx flow, to 115±10 mL/min
(P<.001).
Regional Flow Changes With Setting of
the Mild LAD Stenosis and
After Adenosine Infusion
As shown in Table 2
, no
significant change in epicardial, midwall,
or endocardial flow was seen with setting of the mild LAD stenosis. In
this group, adenosine increased epicardial flow from 1.5±0.2 to
3.6±0.3
mL · min-1 · g-1
(P<.001) in the stenotic zone. Endocardial flow increased
from 1.4±0.1 to 1.7±0.1
mL · min-1 · g-1, although
this
change did not reach statistical significance (P=.086). In
contrast, epicardial and endocardial flows increased to 4.6±0.4 and
3.7±0.3
mL · min-1 · g-1 in the
normally perfused LCx zone after adenosine administration. Thus,
hyperemic flow distal to the mild LAD stenosis consequent to
adenosine-induced vasodilatation occurred, but it was less of a
flow increase than seen in the LCx bed. In this group, no
endocardial-to-epicardial coronary steal was apparent in the LAD
perfusion zone.
201Tl and Sestamibi Activities
in the LAD Zone After
Tracer Administration During Adenosine Infusion
As shown in Fig
5
(right), for this group of dogs, the
stenotic-to-normal count ratios for both 201Tl (0.62±0.04)
and sestamibi (0.79±0.03) significantly underestimated the
stenotic-to-normal flow ratio (0.43±0.04; P<.001). As
observed in the critical stenosis dogs, the underestimation was greater
for sestamibi than for 201Tl (P<.001).
Quantification of Defects on Images of Myocardial Slices in Dogs in
Protocols 2 and 3
In all 7 dogs with critical stenoses that made up
protocol 2,
prominent sestamibi defects were readily apparent in the anteroapical
region on the gamma-camera images of the myocardial slices. Likewise,
in all 9 dogs with mild LAD stenoses in protocol 3, mild anteroapical
defects could be visually identified on sestamibi images. An example
set of images from 1 dog in each group may be seen in Fig 6
. A
comparison between the mean sestamibi defect count
ratio (stenotic to normal) in dogs with severe versus mild LAD stenoses
is shown in Fig 7
. The mean sestamibi defect count ratio
in the critical stenosis group (0.62±0.05) was significantly less than
in the mild stenosis group (0.80±0.02) (P<.01).
|
|
| Discussion |
|---|
|
|
|---|
In dogs with either critical or mild LAD stenoses (protocols 2 and 3), adenosine was administered intravenously to more closely mimic the clinical situation. The dose administered (300 µg · kg-1 · min-1) was chosen empirically to give the largest increase in coronary flow without lowering mean arterial pressure below 85 mm Hg. In these dogs, there was a decrease in mean arterial pressure and a slight but statistically insignificant reflex rise in heart rate during adenosine infusion. Similar findings have been observed in patients undergoing vasodilatation with adenosine.23 In the dogs with critical LAD stenoses, no change in LAD coronary flow with adenosine stress was seen. In dogs, the total abolition of coronary flow reserve corresponds to an approximately 90% coronary stenosis.24 The fourfold increase in LCx flow resulted in a 4:1 flow disparity between the LCx and LAD coronary supply zones at the time when 201Tl, sestamibi, and microspheres were administered. As expected, the magnitude of flow heterogeneity between stenotic and normal perfusion beds was underestimated by both sestamibi and 201Tl, but more so by sestamibi. In the dogs with mild LAD stenoses, although the change in LCx flow was similar to that in the critical stenosis group, the LAD flow doubled after adenosine, resulting in a 2:1 flow disparity between the LCx and LAD. In this situation of a milder LAD stenosis, both tracers again underestimated the flow disparity between the two perfusion beds.
Comparison Between 201Tl and Sestamibi Activities With
Microsphere Flow
Previous studies have examined the myocardial
extraction of either
201Tl or sestamibi at high coronary flow rates. Using
pharmacological stress, several groups of investigators have
demonstrated a progressive decrease in
201Tl5 6 or sestamibi3
extraction
with increasing coronary flow. In this study, we sought to directly
compare the uptakes of 201Tl and sestamibi in the same
experimental animals under several experimental conditions simulating
clinical situations. As in previous studies, we found that the early
uptake of both 201Tl and sestamibi plateaus with increasing
coronary flow, leading to an underestimation of flow at high flow
rates. However, in this study we also determined that the extent of the
underestimation was greater for sestamibi than for 201Tl in
dogs with either critical or mild LAD stenoses. The decreased
extraction of sestamibi relative to 201Tl at high coronary
flow rates raises the theoretical possibility of reduced defect
contrast with sestamibi compared with 201Tl, particularly
with mild stenoses in which it is necessary to resolve the difference
between two high flow rates. Several recent studies support this
possibility. In an experimental study by Melon et al,25
the myocardial retentions of sestamibi and 201Tl were
compared at various times after the tracers were injected in dogs with
a totally occluded LAD during dipyridamole infusion. These
investigators found that myocardial 201Tl tissue retention
matched myocardial blood flow more closely than did sestamibi
retention, and for both of these tracers, at high flow rates the blood
flow match was best early after injection. In another experimental
study, Leon et al20 compared polar map displays of
201Tl and sestamibi administered to dogs with either
moderately stenotic or totally occluded LADs during adenosine infusion.
These investigators showed that sestamibi underestimated the size of
the stenosis territory compared with 201Tl, whereas both
tracers showed similar defect sizes in dogs with totally occluded
coronary arteries. Our study differs from that of Leon et al in several
important aspects. In their experiments, the severity of coronary
stenoses was substantially greater than in our study. In 3 of the 4
dogs composing their "severe stenosis" group, resting baseline
flow was reduced before adenosine infusion. Also, they did not inject
201Tl and sestamibi simultaneously at identical flows
during hyperemia. In the study by Leon et al, 201Tl images
were obtained 8 minutes after injection, whereas sestamibi images were
obtained 60 minutes or longer after tracer injection, which may have
resulted in some sestamibi redistribution.26 Furthermore,
these investigators did not perform postmortem gamma-well scintillation
counting of tracer activities in the myocardium or compare tracer
uptake patterns with an independent measure of regional blood flow.
Nevertheless, both studies are consistent in showing underestimation of
defect size and magnitude of hypoperfusion with sestamibi compared with
201Tl when these tracers are administered during
adenosine-induced flow heterogeneity between stenotic and
normal myocardial perfusion beds.
Similar results have been reported in clinical studies by Narahara et al.18 Patients undergoing symptom-limited exercise stress testing had smaller sestamibi SPECT defect sizes than with stress 201Tl SPECT imaging (42±39.9 versus 52±46.2 g, P<.05). Using another method for quantifying SPECT defect size, Maublant et al19 also found smaller exercise stress defect sizes in patients with sestamibi (4.6±5.2%) than with 201Tl (6.7±5.2%) (P<.05).
Comparison Between 201Tl and Sestamibi Activity by
Gamma-Camera Imaging
In the present study, we obtained gamma-camera
images of ex
vivo slices of the heart directly on the collimator of the camera.
Sestamibi images obtained in this fashion represent ideal
conditions, since there was less scatter and attenuation than with in
vivo imaging to degrade image quality. Since both 201Tl and
sestamibi were administered simultaneously, separation of the pure
201Tl image from the dual isotope mixture is problematic. A
fraction of the 99mTc isotope counts spilling down into the
201Tl window cannot simply be subtracted, as undertaken
with in vitro well counting, because with imaging, spatial factors must
also be taken into account. Although methods for performing this
subtraction are currently being investigated,27 further
validation is necessary before these techniques can be implemented.
Therefore, in this study, quantification was performed only on the
sestamibi images. As shown in Fig 7
, sestamibi defect magnitude
was
significantly greater in critically stenotic than in mildly stenotic
dogs. In the latter group, only an average 20% reduction in sestamibi
counts was observed in the defect region. Nevertheless, defects were
still visually apparent on the scintigrams of the myocardial slices in
all dogs with a mild stenosis.
Transport Kinetics
Fig 4
shows how the
extraction of sestamibi and
201Tl varies with myocardial blood flow. These curves are
characteristic of any extractable tracer in that the amount of tracer
extracted is proportional to flow only at low flow rates (where tracer
extraction is flow limited) and changes to a plateau at high rates, at
which the extraction of tracer becomes limited by membrane transport.
The solid lines of Fig 4
are curve fits of the function
b(1-exp-ps/b), where b is blood flow per unit volume
and
ps is capillary permeability times surface area product. This function
is from the solute transport model as detailed by Gosselin and
Stibitz.28 This is a general model describing an
extractable tracer passing through the capillary bed. The model
accounts for back-diffusion of tracer as well as direct extraction. At
flow rates <1.0
mL · min-1 · g-1,
tracer extraction is limited by blood flow and the amount of extracted
tracer is proportional to blood flow. As flow increases, less tracer is
directly extracted during the capillary transit, and tracer that
diffuses back into the capillary channel is less likely to be
reabsorbed before it reaches the venules. Thus, at very high flow
rates, tracer extraction is determined only by membrane permeability
and is no longer dependent on blood flow.
The model described above fits our experimental data. In this model, the extractable tracer behaves like a perfect (ie, microsphere) tracer only at very low flow rates and progressively underestimates flow relative to the perfect tracer at increasingly higher myocardial flow rates. In clinical imaging, we do not have a perfect flow tracer for comparison and normally use the uptake of the injected tracer in a sample of normally perfused myocardium as a reference standard. Compared with the extraction of 201Tl or sestamibi by normally perfused myocardium, the extraction of these tracers is greater in underperfused beds. Thus, the extraction appears to be enhanced at low flows. The tracer overestimates blood flow in ischemic regions compared with normally perfused regions and underestimates blood flow in regions of relatively elevated blood flow.
The blood flow
dependence of extraction shown in Fig 4
and discussed
above will result in mild underestimation of the amount of flow
reduction when normally perfused myocardium is compared with ischemic
myocardium. Underestimation of relative flow will be greater when
segments with vasodilator-induced hyperemia are compared. The amount of
underestimation depends on tracer extraction, being more pronounced
with tracers that have lower myocardial first-pass extraction.
Limitations of the Study
One potential limitation to the
present study concerns the use
of anesthesia. Anesthesia may have some unknown effect on blood flow
distribution or tracer transport. This was not considered to be a
serious limitation, since the measurements of tracer uptake were
relative rather than absolute measurements. A second limitation was
that in vivo imaging was not performed. With closed-chest in vivo
imaging, attenuation and scatter would have more closely mimicked the
clinical setting. However, unless the two tracers were administered at
different times with separate imaging protocols undertaken, the dual
isotope spill correction problem would still exist. A strength of this
study is that 201Tl and sestamibi were administered
simultaneously to be certain that flow at the time of injection was
identical for both tracers. This permitted valid comparison of
myocardial uptake patterns of these agents during
adenosine-induced hyperemia by use of highly accurate in vitro
gamma-well counting techniques.
Clinical Implications
The results of the present study
suggest that it is
theoretically possible for mild stenoses to be better detected by
201Tl rather than sestamibi in conjunction with vasodilator
stress. However, it should be pointed out that with clinical imaging,
ideal conditions do not exist and other factors such as scatter and
attenuation degrade overall image quality, particularly with the lower
energy of 201Tl. In addition, in this study there was no
appreciable 201Tl redistribution, since the animals were
euthanatized several minutes after tracer injection. Redistribution
will diminish defect magnitude. These degradative factors are greater
for 201Tl than for sestamibi and may offset the difference
in extraction between the tracers at high coronary flow. This may
explain why clinical studies have found similar sensitivities,
specificities, and overall diagnostic accuracy for detection of
coronary artery disease between 201Tl and
sestamibi.8 9 10 11 12 13 14 15 16 17
Further clinical studies are warranted that
compare 201Tl and sestamibi SPECT imaging in the same
patients for detection of mild coronary artery stenoses by use of
vasodilator stress.
A second implication of the present study is related to the use of higher doses of dipyridamole or adenosine to achieve greater flow disparity between normal and stenotic regions. Measurements of coronary flow in humans by use of a Doppler catheter have shown that the standard dose of dipyridamole currently administered (0.56 mg/kg) may not be achieving maximal coronary vasodilation29 and that adenosine is perhaps more effective than dipyridamole for achieving maximal hyperemia.30 Parodi et al31 recently proposed using a higher dose of dipyridamole with sestamibi to improve image contrast. The present study suggests that, because of the plateau in extraction of both 201Tl and sestamibi at coronary flow rates as low as two to three times normal flow, additional pharmacological vasodilatation will add minimal enhanced contrast to the images for defect detection.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received February 3, 1994; accepted August 19, 1994.
| References |
|---|
|
|
|---|
2.
Okada RD, Glover D, Gaffney T, Williams S. Myocardial
kinetics of technetium-99m-hexakis-2-methoxy-2-methylpropyl isonitrile.
Circulation. 1988;77:491-498.
3.
Glover DK, Okada RD. Myocardial kinetics of Tc-MIBI in canine
myocardium after dipyridamole. Circulation. 1990;81:628-636.
4. Strauss HW, Pitt B. Noninvasive detection of subcritical coronary arterial narrowings with a coronary vasodilator and myocardial perfusion imaging. Am J Cardiol. 1976;39:403-406.
5. Mays AE, Cobb FR. Relationship between regional myocardial blood flow and thallium-201 distribution in the presence of coronary artery stenosis and dipyridamole-induced vasodilation. J Clin Invest. 1984;73:1359-1366.
6.
Weich HF, Strauss HW. The extraction of thallium-201 by the
myocardium. Circulation. 1977;56:188-191.
7.
Leppo JA, Meerdink DJ. Comparison of the myocardial uptake of
a technetium-labeled isonitrile analogue and thallium. Circ
Res. 1989;65:632-639.
8. Kiat H, Maddahi J, Roy LT, Van Train K, Friedman J, Resser K, Berman DS. Comparison of technetium-99m methoxy isobutyl isonitrile and thallium-201 for evaluation of coronary artery disease by planar and tomographic methods. Am Heart J. 1989;117:1-11. [Medline] [Order article via Infotrieve]
9.
Wackers FJTH, Berman DS, Maddahi J, Watson DD, Beller
GA, Strauss HW, Boucher CA, Picard M, Holman BL, Fridrich R, Inglese E,
Delaloye B, Bischof-Delaloye A, Camin L, McKusick K. Technetium-99m
hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry,
safety, and preliminary comparison to thallium-201 for myocardial
perfusion imaging. J Nucl Med. 1989;30:301-311.
10. Najm YC, Maisey MN, Clarke SM, Fogelman I, Curry PVL, Sowton E. Exercise myocardial perfusion scintigraphy with technetium-99m methoxy isobutylisonitrile: a comparative study with thallium-201. Int J Cardiol. 1990;26:93-102. [Medline] [Order article via Infotrieve]
11. Taillefer R, Lambert R, Dupras G, Gregoire J, Leveille J, Essiambre R, Phaneuf DC. Clinical comparison between thallium-201 and 99mTc-isobutyl isonitrile (hexamibi) myocardial perfusion imaging for detection of coronary artery disease. Eur J Nucl Med. 1989;15:280-286. [Medline] [Order article via Infotrieve]
12.
Kahn JK, McGhie I, Akers MS, Sills MN, Faber TL, Kulkami PV,
Willerson JT, Corbett JR. Quantitative rotational tomography with
Tl-201 and Tc99m-2-methoxyisobutyl-isonitrile: a direct comparison in
normal individuals and patients with coronary artery disease.
Circulation. 1989;79:1282-1293.
13. Iskandrian AS, Heo J, Kong B, Lyons E, Marsch S. Use of technetium-99m isonitrile (RP-30A) in assessing left ventricular perfusion and function at rest and during exercise in coronary artery disease, and comparison with coronary arteriography and exercise thallium-201 SPECT imaging. Am J Cardiol. 1989;64:270-275. [Medline] [Order article via Infotrieve]
14.
Sinusas AJ, Beller GA, Smith WH, Vinson EL, Brookeman V,
Watson DD. Quantitative planar imaging with technetium-99m
methoxyisobutyl isonitrile: comparison of uptake patterns with
thallium-201. J Nucl Med. 1989;30:1456-1463.
15.
Tartagni F, Dondi M, Limonetti P, Franchi R, Maiello L,
Monetti N, Magnani B. Dipyridamole technetium-99m-2-methoxy isobutyl
isonitrile tomoscintigraphic imaging for identifying diseased coronary
vessels: comparison with thallium-201 stress-rest study. J
Nucl Med. 1991;32:369-376.
16.
Marwick T, Willemart B, D'Hondt A, Baudhuin T, Wijns W,
Detry
J, Melin J. Selection of the optimal nonexercise stress for the
evaluation of ischemic regional myocardial dysfunction and
malperfusion: comparison of dobutamine and adenosine using
echocardiography and Tc-99m-MIBI single photon emission computed
tomography. Circulation. 1993;87:345-354.
17. Taillefer R. Technetium-99m sestamibi myocardial imaging: same day rest-stress studies and dipyridamole. Am J Cardiol. 1990;66:80E-84E. [Medline] [Order article via Infotrieve]
18. Narahara KA, Villanueva-Meyer J, Thompson CJ, Brizendine M, Mena I. Comparison of thallium-201 and technetium-99m hexakis 2-methoxyisobutyl isonitrile single photon emission computed tomography for estimating the extent of myocardial ischemia and infarction in coronary artery disease. Am J Cardiol. 1990;66:1438-1444. [Medline] [Order article via Infotrieve]
19. Maublant JC, Marcaggi X, Lusson JR, Boire JY, Cauvin JC, Jacob P, Veyre A, Cassagnes J. Comparison between thallium-201 and technetium-99m methoxyisobutyl isonitrile defect size in single-photon emission computed tomography at rest, exercise and redistribution in coronary artery disease. Am J Cardiol. 1992;69:183-187. [Medline] [Order article via Infotrieve]
20. Leon AR, Eisner RL, Martin SE, Schmarkey LS, Aaron AM, Boyers AS, Burnham KM, Oh DJ, Patterson RE. Comparison of single-photon emission computed tomographic (SPECT) myocardial perfusion imaging with thallium-201 and technetium-99m sestamibi in dogs. J Am Coll Cardiol. 1992;20:1612-1625. [Abstract]
21. Heymann MA, Payne BD, Hoffman JIE, Rudolph AM. Blood flow measurements with radionuclide-labeled particles. Prog Cardiovasc Dis. 1987;20:55-79.
22.
Wilson RF, Wyche K, Christensen BSN, Zimmer S, Laxson DD.
Effects of adenosine on human coronary arterial circulation.
Circulation. 1990;82:1595-1606.
23.
Verani MS, Mahmarian JJ, Hixson JB, Boyce TM, Staudacher RA.
Diagnosis of coronary artery disease by controlled coronary
vasodilation with adenosine and thallium-201 scintigraphy in patients
unable to exercise. Circulation. 1990;82:80-87.
24. Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis. Am J Cardiol. 1974;33:87-94. [Medline] [Order article via Infotrieve]
25. Melon PG, Beanlands RS, DeGrado TR, Nguyen N, Petry NA, Schwaiger M. Comparison of technetium-99m sestamibi and thallium-201 retention characteristics in canine myocardium. J Am Coll Cardiol. 1992;20:1277-1283. [Abstract]
26.
Sinusas AJ, Bergin JD, Edwards NC, Watson DD, Ruiz M, Makuch
RW, Smith WH, Beller GA. Redistribution of 99mTc-sestamibi
and 201Tl in the presence of a severe coronary artery
stenosis. Circulation. 1994;89:2332-2341.
27. Smith WH, Kurowski CJ, Sobczak M, Beller GA, Watson DD. Enhanced spill correction techniques enable recovery of pure 201Tl image in dual-isotope imaging of Tc-99m and Tl-201. J Nucl Med. 1991;32:1059. Abstract.
28. Gosselin RE, Stibitz GR. Rates of solute absorption from tissue depots: theoretical considerations. Pflugers Arch. 1970;318:85-98. [Medline] [Order article via Infotrieve]
29.
Wilson RF, Laughlin DE, Ackell PH, Chilian WM, Holida MD,
Hartley CJ, Armstrong ML, Marcus ML, White CW. Transluminal
subselective measurement of coronary artery blood flow velocity and
vasodilator reserve in man. Circulation. 1985;72:82-92.
30. Rossen JD, Quillen JE, Lopez AG, Stenberg RG, Talman CL, Winniford MD. Comparison of coronary vasodilation with intravenous dipyridamole and adenosine. J Am Coll Cardiol. 1991;18:485-491. [Abstract]
31. Parodi O, Marcassa C, Casucci R, Sumbuceti G, Verna E, Galli M, Inglese E, Marzullo P, Pirelli S, Bisi G, Giubbini R, Scopinaro F. Accuracy and safety of technetium-99m hexakis 2-methoxy-2-isobutyl isonitrile (sestamibi) myocardial scintigraphy with high dose dipyridamole test in patients with effort angina pectoris: a multicenter study. J Am Coll Cardiol. 1991;18:1439-1444.[Abstract]
This article has been cited by other articles:
![]() |
G. A. Beller and D. D. Watson A Welcomed New Myocardial Perfusion Imaging Agent for Positron Emission Tomography Circulation, May 5, 2009; 119(17): 2299 - 2301. [Full Text] [PDF] |
||||
![]() |
T. F. Christian, D. W. Rettmann, A. H. Aletras, S. L. Liao, J. L. Taylor, R. S. Balaban, and A. E. Arai Absolute Myocardial Perfusion in Canines Measured by Using Dual-Bolus First-Pass MR Imaging Radiology, September 1, 2004; 232(3): 677 - 684. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Lee, O. P. Simonetti, K. R. Harris, T. A. Holly, R. M. Judd, E. Wu, and F. J. Klocke Magnetic Resonance Versus Radionuclide Pharmacological Stress Perfusion Imaging for Flow-Limiting Stenoses of Varying Severity Circulation, July 6, 2004; 110(1): 58 - 65. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Peltier, D. Vancraeynest, A. Pasquet, T. Ay, V. Roelants, A.-M. D'hondt, J. A. Melin, and J.-L. J. Vanoverschelde Assessment of the physiologic significance of coronary disease with dipyridamole real-time myocardial contrast echocardiography: Comparison with technetium-99m sestamibi single-photon emission computed tomography and quantitative coronary angiography J. Am. Coll. Cardiol., January 21, 2004; 43(2): 257 - 264. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ruiz, K. Takehana, F. D. Petruzella, D. D. Watson, G. A. Beller, and D. K. Glover Arbutamine Stress Perfusion Imaging in Dogs with Critical Coronary Artery Stenoses: 99mTc-Sestamibi Versus 201Tl J. Nucl. Med., May 1, 2002; 43(5): 664 - 670. [Abstract] [Full Text] [PDF] |
||||
![]() |
P Lancellotti, T Benoit, P Rigo, and L A Pierard Dobutamine stress echocardiography versus quantitative technetium-99m sestamibi SPECT for detecting residual stenosis and multivessel disease after myocardial infarction Heart, November 1, 2001; 86(5): 510 - 515. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Taki, S. Fujino, K. Nakajima, I. Matsunari, H. Okazaki, T. Saga, H. Bunko, and N. Tonami 99mTc-Sestamibi Retention Characteristics During Pharmacologic Hyperemia in Human Myocardium: Comparison with Coronary Flow Reserve Measured by Doppler Flowire J. Nucl. Med., October 1, 2001; 42(10): 1457 - 1463. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Glover, M. Ruiz, K. Takehana, F. D. Petruzella, L. M. Riou, J. M. Rieger, T. L. Macdonald, D. D. Watson, J. Linden, and G. A. Beller Pharmacological Stress Myocardial Perfusion Imaging With the Potent and Selective A2A Adenosine Receptor Agonists ATL193 and ATL146e Administered by Either Intravenous Infusion or Bolus Injection Circulation, September 4, 2001; 104(10): 1181 - 1187. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Takehana, G. A. Beller, M. Ruiz, F. D. Petruzella, D. D. Watson, and D. K. Glover Assessment of Residual Coronary Stenoses Using 99mTc-N-NOET Vasodilator Stress Imaging to Evaluate Coronary Flow Reserve Early After Coronary Reperfusion in a Canine Model of Subendocardial Infarction J. Nucl. Med., September 1, 2001; 42(9): 1388 - 1394. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Fagret, C. Ghezzi, and G. Vanzetto 99mTc-N-NOET Imaging for Myocardial Perfusion: Can It Offer More Than We Already Have? J. Nucl. Med., September 1, 2001; 42(9): 1395 - 1396. [Full Text] [PDF] |
||||
![]() |
I. Matsunari, F. Haas, N. T.B. Nguyen, G. Reidel, I. Wolf, R. Senekowitsch-Schmidtke, G. Stöcklin, and M. Schwaiger Comparison of Sestamibi, Tetrofosmin, and Q12 Retention in Porcine Myocardium J. Nucl. Med., May 1, 2001; 42(5): 818 - 823. [Abstract] [Full Text] |
||||
![]() |
K. Wei, E. Le, J.-P. Bin, M. Coggins, A. R. Jayawera, and S. Kaul Mechanism of reversible 99mTc-sestamibi perfusion defects during pharmacologically induced vasodilatation Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1896 - H1904. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Soman, R. Taillefer, E. G. DePuey, J. E. Udelson, and A. Lahiri Enhanced detection of reversible perfusion defects by Tc-99m sestamibi compared to Tc-99m tetrofosmin during vasodilator stress SPECT imaging in mild-to-moderate coronary artery disease J. Am. Coll. Cardiol., February 1, 2001; 37(2): 458 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Leistad, K. Ohmori, T. A. Peterson, G. Christensen, and A. N. DeMaria Quantitative assessment of myocardial perfusion during graded coronary artery stenoses by intravenous myocardial contrast echocardiography J. Am. Coll. Cardiol., February 1, 2001; 37(2): 624 - 631. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-X. He, E. Cwajg, W. Hwang, C. J. Hartley, E. Funk, L. H. Michael, and M. S. Verani Myocardial Blood Flow and Myocardial Uptake of 201Tl and 99mTc-Sestamibi During Coronary Vasodilation Induced by CGS-21680, a Selective Adenosine A2A Receptor Agonist Circulation, July 25, 2000; 102(4): 438 - 444. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Takehana, M. Ruiz, F. D. Petruzella, D. D. Watson, G. A. Beller, and D. K. Glover Response to incremental doses of dobutamine early after reperfusion is predictive of the degree of myocardial salvage in dogs with experimental acute myocardial infarction J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1960 - 1968. [Abstract] [Full Text] [PDF] |
||||
![]() |
I Jucquois, P Nihoyannopoulos, A-M D'Hondt, V Roelants, A Robert, J A Melin, D Glass, and J-L J Vanoverschelde Comparison of myocardial contrast echocardiography with NC100100 and 99mTc sestamibi SPECT for detection of resting myocardial perfusion abnormalities in patients with previous myocardial infarction Heart, May 1, 2000; 83(5): 518 - 524. [Abstract] [Full Text] |
||||
![]() |
D. A. Calnon, M. Ruiz, G. Vanzetto, D. D. Watson, G. A. Beller, and D. K. Glover Myocardial Uptake of 99mTc-N-NOET and 201Tl During Dobutamine Infusion : Comparison With Adenosine Stress Circulation, October 12, 1999; 100(15): 1653 - 1659. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Bartunek, W. Wijns, G. R. Heyndrickx, and B. de Bruyne Effects of Dobutamine on Coronary Stenosis Physiology and Morphology : Comparison With Intracoronary Adenosine Circulation, July 20, 1999; 100(3): 243 - 249. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Vanzetto, D. A. Calnon, M. Ruiz, D. D. Watson, R. Pasqualini, G. A. Beller, and D. K. Glover Myocardial Uptake and Redistribution of 99mTc-N-NOET in Dogs With Either Sustained Coronary Low Flow or Transient Coronary Occlusion : Comparison With 201Tl and Myocardial Blood Flow Circulation, October 7, 1997; 96(7): 2325 - 2331. [Abstract] [Full Text] |
||||
![]() |
D. K. Glover, M. Ruiz, J. Y. Yang, W. H. Smith, D. D. Watson, and G. A. Beller Myocardial 99mTc-Tetrofosmin Uptake During Adenosine-Induced Vasodilatation With Either a Critical or Mild Coronary Stenosis : Comparison With 201Tl and Regional Myocardial Blood Flow Circulation, October 7, 1997; 96(7): 2332 - 2338. [Abstract] [Full Text] |
||||
![]() |
D. A. Calnon, D. K. Glover, G. A. Beller, G. Vanzetto, W. H. Smith, D. D. Watson, and M. Ruiz Effects of Dobutamine Stress on Myocardial Blood Flow, 99mTc Sestamibi Uptake, and Systolic Wall Thickening in the Presence of Coronary Artery Stenoses : Implications for Dobutamine Stress Testing Circulation, October 7, 1997; 96(7): 2353 - 2360. [Abstract] [Full Text] |
||||
![]() |
D. K. Glover, M. Ruiz, J. Y. Yang, B. A. Koplan, T. R. Allen, W. H. Smith, D. D. Watson, R. J. Barrett, and G. A. Beller Pharmacological Stress Thallium Scintigraphy With 2-Cyclohexylmethylidenehydrazinoadenosine (WRC-0470): A Novel, Short-Acting Adenosine A2A Receptor Agonist Circulation, October 1, 1996; 94(7): 1726 - 1732. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |